KineMed and Camino Partner to Acquire Drug Candidates | GenomeWeb

NEW YORK (GenomeWeb) – KineMed and Camino Partnership today announced that they are partnering in an effort to acquire new drugs and targeted drug candidates for potential licensing opportunites.

According to the partners, KineMed plans to apply its proteomics technology in rapid proof-of-concept studies on up to six compounds over a three-year period and then out-license appropriate candidate drugs to pharmaceutical companies.

Initially, the effort will focus on drugs for oncology, neurodegenerative disorders, muscle wasting, and fibrosis diseases, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.